# ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

> clinical trial · VERIFIED · 2026-08-11

Status: RECRUITING · Sponsor: Newave Pharmaceutical Inc · Condition: CLL / SLL

- Company: Newave Pharmaceutical Inc
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT07342478

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.